Search results
Results from the WOW.Com Content Network
This page was last edited on 18 September 2023, at 12:07 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
ATC code C10 Lipid modifying agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
The statin use may require that the warfarin dose be changed, as some statins increase the effect of warfarin. [ 64 ] The most important adverse side effects are muscle problems, an increased risk of diabetes mellitus , and increased liver enzymes in the blood due to liver damage .
Statin-induced rhabdomyolysis is rare, occurring in less than 0.1% of people who take statins. [ 66 ] [ 67 ] [ 68 ] Statin induced rhabdomyolysis, as with other statin associated muscle symptoms, occurs most commonly in the first year of treatment but can occur at any time during treatment. [ 66 ]
Statins are a competitive antagonists of HMG CoA, as they directly compete with the endogenous substrate for the active site cavity of HMGR. Statins are also noncompetitive with the cosubstrate NADPH (nicotinamide adenine dinucleotide phosphate). [5] By blocking the HMGR enzyme they inhibit the synthesis of cholesterol via the mevalonate pathway.
This is the list of Schedule III controlled substances in the United States as defined in section 202 of the Controlled Substances Act (21 U.S.C. § 812) and 21 CFR 1308.13. The following findings are required for substances to be placed in this schedule:
The pharmacological results from cerivastatin show that it is the most active HMG-CoA-reductase inhibitor among reported statins. Due to its high enzyme affinity, it would seem to offer ultra-low dose therapy in the microgram range. However, due to its relatively severe adverse effects in comparison to other statins, its market use was ...
The effects of rosuvastatin on low-density lipoprotein (LDL) cholesterol are dose-related. Higher doses were more efficacious in improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin.